TFCM
TCRT icon

Taylor Frigon Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Taylor Frigon Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$2K Buy
+3
New +$3.27K ﹤0.01% 89
2016
Q1 		– Sell
-3
Closed -$3K – 91
2015
Q4 		$3K Hold
3
– – ﹤0.01% 83
2015
Q3 		$4K Buy
+3
New +$4.95K ﹤0.01% 77

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Taylor Frigon Capital Management's TCRT Position: Q2 2016 in Review

Taylor Frigon Capital Management opened a new position in Alaunos Therapeutics (TCRT) in Q2 2016: 3 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #89 among its holdings. This is a return to the name: Taylor Frigon Capital Management previously reported a position in TCRT as recently as Q4 2015.

Taylor Frigon Capital Management first reported a position in TCRT in Q3 2015 and has held it in 3 quarters since. The position peaked at $4K in Q3 2015. 154 funds tracked by Wall St. Rank hold TCRT as of Q2 2016.

  • Taylor Frigon Capital Management held 3 shares of Alaunos Therapeutics worth $2K as of Q2 2016.
  • Alaunos Therapeutics was a new Taylor Frigon Capital Management position in Q2 2016.
  • Alaunos Therapeutics made up ﹤0.01% of Taylor Frigon Capital Management's portfolio in Q2 2016, its #89 holding.
  • Taylor Frigon Capital Management first reported a position in Alaunos Therapeutics in Q3 2015 and has held it in 3 quarters since.
  • Taylor Frigon Capital Management's Alaunos Therapeutics position peaked at $4K in Q3 2015.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2016.

Based on Taylor Frigon Capital Management's 13F filing for Q2 2016, filed 3 Aug 2016.